New Pur­due bank­rupt­cy plan round­ly crit­i­cized as Sack­lers of­fer $4B+; Sana seals pact with Fu­ji­film for iP­SC-de­rived ther­a­pies

Mem­bers of the Sack­ler fam­i­ly caught up in thou­sands of law­suits tar­get­ing them and Pur­due Phar­ma for their in­volve­ment in the opi­oid epi­dem­ic have agreed to hand over $4.3 bil­lion of their for­tune in ex­change for be­ing left off the hook of lit­i­ga­tion.

That fig­ure marks a sig­nif­i­cant in­crease over the $3 bil­lion that had been on of­fer, and it was im­me­di­ate­ly at­tacked by a host of crit­ics who be­lieve they should be re­quired to give up much, much more af­ter prof­it­ing from the reck­less dis­tri­b­u­tion of Oxy­Con­tin. The opi­oid epi­dem­ic is re­spon­si­ble for the deaths of hun­dreds of thou­sands of peo­ple.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER